Below are the most recent publications written about "Toll-Like Receptor 9" by people in Profiles.
-
Ward JM, Ratliff ML, Dozmorov MG, Wiley G, Guthridge JM, Gaffney PM, James JA, Webb CF. Human effector B lymphocytes express ARID3a and secrete interferon alpha. J Autoimmun. 2016 Dec; 75:130-140.
-
Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013 Jun; 123(6):2447-63.
-
Peters AL, Plenge RM, Graham RR, Altshuler DM, Moser KL, Gaffney PM, Bishop GA. A novel polymorphism of the human CD40 receptor with enhanced function. Blood. 2008 Sep 01; 112(5):1863-71.
-
Welner RS, Pelayo R, Nagai Y, Garrett KP, Wuest TR, Carr DJ, Borghesi LA, Farrar MA, Kincade PW. Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection. Blood. 2008 Nov 01; 112(9):3753-61.
-
Wuest T, Austin BA, Uematsu S, Thapa M, Akira S, Carr DJ. Intact TRL 9 and type I interferon signaling pathways are required to augment HSV-1 induced corneal CXCL9 and CXCL10. J Neuroimmunol. 2006 Oct; 179(1-2):46-52.
-
Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006 Jul; 4(7):437-47.
-
Klinman DM, Zeuner R, Yamada H, Gursel M, Currie D, Gursel I. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann N Y Acad Sci. 2003 Dec; 1002:112-23.
-
Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003 Aug 01; 171(3):1393-400.